Brought to you by 
Genocea secures up to $27mm in debt financing from Hercules, plus $2mm in equity financing
24 Nov 2014
Executive Summary
Nine months after going public, Genocea Biosciences Inc. (T-cell vaccines for infectious diseases) secured up to $27mm in debt financing from Hercules Technology Growth Capital, which provided $12mm up front. At its option, Genocea can draw down another $5mm no later than June 30, 2015, and two additional tranches of $5mm on or before December 15, 2015. The tranches are subject to Phase II clinical milestones for its GEN003 and GEN004, and the close of future equity financing. Hercules also purchased $2mm in Genocea equity--223k common shares at $8.95 each (a slight premium).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Financing
- Nonconvertible Debt
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genocea secures up to $27mm in debt financing from Hercules, plus $2mm in equity financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice